A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
暂无分享,去创建一个
Angela Greco | Rossella Bertulli | Marco A Pierotti | Silvana Pilotti | Elena Tamborini | P. Casali | M. Pierotti | T. Negri | S. Pilotti | A. Gronchi | M. Colecchia | V. Albertini | R. Bertulli | E. Tamborini | L. Bonadiman | A. Greco | Maurizio Colecchia | Alessandro Gronchi | Paolo G Casali | Lorena Bonadiman | Veronica Albertini | Tiziana Negri | Veronica Albertini
[1] T. Jacks,et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.
[2] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[3] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[4] M. Pierotti,et al. The Gly571arg mutation, associated with the autonomic and sensory disorder congenital insensitivity to pain with anhidrosis, causes the inactivation of the NTRK1/nerve growth factor receptor , 2000, Journal of cellular physiology.
[5] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[6] Peter Marynen,et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.
[7] T. Hunter,et al. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.
[8] J. Eary,et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] B. Druker,et al. Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571* , 2002, The Journal of Biological Chemistry.
[10] M. Pierotti,et al. c-KIT and c-KIT ligand (SCF) in synovial sarcoma (SS): an mRNA expression analysis in 23 cases , 2001, British Journal of Cancer.
[11] K. Walsh. The Protein Kinase Family , 1987 .
[12] B. Druker,et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Antonescu,et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans , 2002, International journal of cancer.
[14] B. Druker,et al. STI571: a paradigm of new agents for cancer therapeutics. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] H. Serve,et al. A Single Amino Acid Exchange Inverts Susceptibility of Related Receptor Tyrosine Kinases for the ATP Site Inhibitor STI-571* 210 , 2003, The Journal of Biological Chemistry.
[16] G. Daley,et al. Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.
[17] G. Demetri,et al. Management of malignant gastrointestinal stromal tumours. , 2002, The Lancet. Oncology.
[18] P. Rosée,et al. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective , 2002, Leukemia.
[19] C. Fletcher,et al. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. , 2002, American journal of clinical pathology.
[20] J. Lasota,et al. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.